
Novo Nordisk now has a 30.3 percent share of the diabetes market, and is well on the way to achieving its long-term goal of controlling a third of the market. In 2019, the company’s market share was 28 percent.
Executive Vice President for Commercial Strategy and Corporate Affairs Camilla Sylvest mentioned this goal at Novo’s capital markets day, saying that over the next few years, growth is expected to be driven by GLP-1 products like tablet Rybelsus and the company’s best-selling drug Ozempic.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app